Inclusion of drugs in provincial drug benefit programs: Who is making these decisions, and are they the right ones?

Laupacis, Andreas
January 2002
CMAJ: Canadian Medical Association Journal;1/8/2002, Vol. 166 Issue 1, p44
Academic Journal
Presents an essay which describes the organization of the Drug Quality and Therapeutics Committee (DQTC) of the Ontario Ministry of Health and Long-Term Care, the annual budget of the Ontario Drug Benefits Program (ODBP), and the major drugs the program funds. Thoughts on the use of information concerning the cost-effectiveness of drugs in general; Organization and process of the DQTC; Annual budget of the ODBP; Prescription of drugs.


Related Articles

  • Pharmacy changes in Ontario: New professional services, remote dispensing and more.  // Canadian Pharmacists Journal (Allen Press Publishing Services In;May/Jun2011, Vol. 144 Issue 3, p104 

    The article offers information on the Ontario Drug Benefit (ODB) program in Ontario. It states that the program will allow pharmacists to receive 15 U.S. dollars fee for services such as pharmaceutical opinion. It cites that the program can make pharmacists to measure the value of the care that...

  • Public Health Watch.  // Canadian Pharmacists Journal (Allen Press Publishing Services In;Sep/Oct2011, Vol. 144 Issue 5, p209 

    The article offers world news briefs related to public health. According to a Canadian study, patients in Africa who take HIV drugs can expect to have a near normal lifespan. The Ontario government began funding prescriptions for smoking cessation drugs through the Ontario Drug Benefit Program....

  • Initial patterns of use of COX-2 inhibitors by elderly patients in Ontario: findings and implications. Mamdani, Muhammad; Rochon, Paula; Laupacis, Andreas; Anderson, Geoffrey // CMAJ: Canadian Medical Association Journal;11/12/2002, Vol. 167 Issue 10, p1125 

    Examines the impact of listing cyclooxygenase-2 (COX-2) inhibitors on the Ontario Drug Benefit (ODB) formulary relative to the costs of overall nonsteroidal anti-inflammatory drugs (NSAID). How ODB first listed COX-2 inhibitors celecoxib (Celebrex) and rofecoxib (Vioxx) as limited use;...

  • Ontario Okays Prezista.  // Guide;Jul2007, Vol. 27 Issue 7, p89 

    The article reports on the approval of Prezista, a protease inhibitor made by Tibotec, by Health Canada. The Drug has been added to the Ontario Drug Benefit Formulary. The cost of Prezista will also be covered under the Ontario Drug Benefit Program. The Common Drug Review has recommended the...

  • Impact of Antibiotic Administrative Restrictions on Trends in Antibiotic Resistance. Marshall, D. A.; Simonyi, S.; A. McGeer; Green, K.; J. Gough; Jaszewski, B.; P. Grootendorst; MacLeod, S. M.; M. Buitendyk; Low, D. E. // Canadian Journal of Public Health;Mar/Apr2006, Vol. 97 Issue 2, p126 

    Context: In March 2001, in response to concerns about increasing resistance to fluoroquinolone (FQ) antibiotics, the Ontario Drug Benefit (ODB) program limited reimbursement of FQs to ODB beneficiaries defined as high risk or in whom other therapies are not tolerated. Objective: To analyze the...

  • MAXIMUS Awarded Three-Year, $11 Mln (CDN) Administrative Services Contract for the Ontario Drug Benefit Program.  // Biomedical Market Newsletter;2/14/2012, Vol. 21, p1 

    The article offers information related to an announcement made by MAXIMUS regarding signing a new contract with the Government of Ontario's Ministry of Health and Long Term Care in order to provide administrative services for the Ontario Drug Benefit Program. Richard Montoni, Chief Executive...

  • How can employers manage rising drug prices? Hendron-Klein, Kathleen // Credit Union Magazine;Sep2000, Vol. 66 Issue 9, p38 

    No abstract available.

  • Physicians' Perceptions About Managed Care Restrictions on Antibiotic Prescribing. Hasty, Michael; Schrager, Jason; Wrenn, Keith // JGIM: Journal of General Internal Medicine;Dec1999, Vol. 14 Issue 12, p756 

    The purpose of this study was to compare physicians' perceptions about managed care restrictions on drug prescribing with objective measures of the restrictions' effects. When asked a general question, 17 emergency medicine physicians in one urban, university hospital answered that they had to...

  • ATC/DDD methodology: a country perspective.  // WHO Drug Information;2001, Vol. 15 Issue 1, p27 

    Focuses on the impact of the rapid increase of drug consumption in Estonia. Importance of classifications system in measuring drug use; Implementation of Anatomical Therapeutic Chemical and Defined Daily Use systems for regulatory and scientific purposes; Establishment of reforms in the health...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics